From alpha to omega with Aβ: Targeting the multiple molecular appearances of the pathogenic peptide in Alzheimer's disease

Current Medicinal Chemistry

Volumn 17, Issue 3, 2010, Pages 198-212

  De Kimpe, L ^a   Scheper, W ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

amyloid; Aggregation; Alzheimer's disease; Amino acid modification; Proteolysis; Secretase; Therapy

Indexed keywords

ALPHA SECRETASE; ALZHEIMER DISEASE VACCINE; AMINO ACID; AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; BAPINEUZUMAB; BETA SECRETASE; BETA SECRETASE 1; BETA SECRETASE INHIBITOR; BMS 708163; CARBON 11; CLIOQUINOL; EHT 0202; ETAZOLATE; GAMMA SECRETASE; GAMMA SECRETASE INHIBITOR; GINSENOSIDE RG 3; HOMOTAURINE; INSULINASE; LY 2062430; MEMBRANE METALLOENDOPEPTIDASE; METALLOPROTEINASE INHIBITOR; N2 [2 (3,5 DIFLUOROPHENYL) 2 HYDROXYACETYL] N1 (6,7 DIHYDRO 5 METHYL 6 OXO 5H DIBENZ[B,D]AZEPIN 7 YL)ALANINAMIDE; NONSTEROID ANTIINFLAMMATORY AGENT; OLIGOMER; PEPTIDASE; PITTSBURGH COMPOUND B; PROTEINASE; PYROGLUTAMIC ACID; SEMAGACESTAT; SOMATOSTATIN; TARENFLURBIL; TRACER; UNCLASSIFIED DRUG; UNINDEXED DRUG; TAU PROTEIN;

ALZHEIMER DISEASE; AMINO ACID SEQUENCE; AMINO TERMINAL SEQUENCE; CARBOXY TERMINAL SEQUENCE; CLINICAL TRIAL; DRUG EFFECT; DRUG TARGETING; ENZYME ACTIVITY; GLIA CELL; HUMAN; NEUROTOXICITY; NONHUMAN; PATHOGENESIS; PROTEIN AGGREGATION; PROTEIN DEGRADATION; PROTEIN SYNTHESIS; REVIEW; UNSPECIFIED SIDE EFFECT; DRUG ANTAGONISM; DRUG DELIVERY SYSTEM; METABOLISM; METHODOLOGY; MOLECULAR GENETICS; SENILE PLAQUE;

ALZHEIMER DISEASE; AMINO ACID SEQUENCE; AMYLOID BETA-PROTEIN; DRUG DELIVERY SYSTEMS; HUMANS; MOLECULAR SEQUENCE DATA; SENILE PLAQUES; TAU PROTEINS;

EID: 77149162414     PISSN: 09298673     EISSN: None     Source Type: Journal    
DOI: 10.2174/092986710790149765     Document Type: Review

References (178)

1. Thal, D.R.; Rub, U.; Orantes, M.; Braak, H. Phases of A betadeposition in the human brain and its relevance for the development of AD. Neurology, 2002, 58, 1791-1800.
2. Hardy, J. and Selkoe, D.J. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science, 2002, 297, 353-6.
3. Citron, M.; Westaway, D.; Xia, W.; Carlson, G.; Diehl, T.; Levesque, G.; Johnson-Wood, K.; Lee, M.; Seubert, P.; Davis, A.; Kholodenko, D.; Motter, R.; Sherrington, R.; Perry, B.; Yao, H.; Strome, R.; Lieberburg, I.; Rommens, J.; Kim, S.; Schenk, D.; Fraser, P.; St George Hyslop, P.; Selkoe, D.J. Mutant presenilins of Alzheimer's disease increase production of 42-residue amyloid beta-protein in both transfected cells and transgenic mice. Nat. Med., 1997, 3, 67-72.
4. De Strooper, B.; Saftig, P.; Craessaerts, K.; Vanderstichele, H.; Guhde, G.; Annaert, W.; Von Figura, K.; Van Leuven, F. Deficiency of presenilin-1 inhibits the normal cleavage of amyloid precursor protein. Nature, 1998, 391, 387-90.
5. Duff, K.; Eckman, C.; Zehr, C.; Yu, X.; Prada, C.M.; Perez-tur, J.; Hutton, M.; Buee, L.; Harigaya, Y.; Yager, D.; Morgan, D.; Gordon, M.N.; Holcomb, L.; Refolo, L.; Zenk, B.; Hardy, J.; Younkin, S. Increased amyloid-beta42(43) in brains of mice expressing mutant presenilin 1. Nature, 1996, 383, 710-3.
6. Goate, A.; Chartierharlin, M.C.; Mullan, M.; Brown, J.; Crawford, F.; Fidani, L.; Giuffra, L.; Haynes, A.; Irving, N.; James, L.; Mant, R.; Newton, P.; Rooke, K.; Roques, P.; Talbot, C.; Pericakvance, M.; Roses, A.; Williamson, R.; Rossor, M.; Owen, M.; Hardy, J. Segregation of A Missense Mutation in the Amyloid Precursor Protein Gene with Familial Alzheimers-Disease. Nature, 1991, 349, 704-706.
7. Scheuner, D.; Eckman, C.; Jensen, M.; Song, X.; Citron, M.; Suzuki, N.; Bird, T.D.; Hardy, J.; Hutton, M.; Kukull, W.; Larson, E.; Levy-Lahad, E.; Viitanen, M.; Peskind, E.; Poorkaj, P.; Schellenberg, G.; Tanzi, R.; Wasco, W.; Lannfelt, L.; Selkoe, D.; Younkin, S. Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease. Nat. Med., 1996, 2, 864-70.
8. Lott, I.T. and Head, E. Alzheimer disease and Down syndrome: factors in pathogenesis. Neurobiol. Aging, 2005, 26, 383-9.
9. Cabrejo, L.; Guyant-Marechal, L.; Laquerriere, A.; Vercelletto, M.; De la Fourniere, F.; Thomas-Anterion, C.; Verny, C.; Letournel, F.; Pasquier, F.; Vital, A.; Checler, F.; Frebourg, T.; Campion, D.; Hannequin, D. Phenotype associated with APP duplication in five families. Brain, 2006, 129, 2966-2976.
10. Corder, E.H.; Saunders, A.M.; Strittmatter, W.J.; Schmechel, D.E.; Gaskell, P.C.; Small, G.W.; Roses, A.D.; Haines, J.L.; Pericakvance, M.A. Gene Dose of Apolipoprotein-e Type-4 Allele and the Risk of Alzheimers-Disease in Late-Onset Families. Science, 1993, 261, 921-923.
11. Deane, R.; Sagare, A.; Hamm, K.; Parisi, M.; Lane, S.; Finn, M.B.; Holtzman, D.M.; Zlokovic, B.V. apoE isoform-specific disruption of amyloid beta peptide clearance from mouse brain. J. Clin. Invest., 2008, 118, 4002-4013.
12. Selkoe, D.J. The cell biology of beta-amyloid precursor protein and presenilin in Alzheimer's disease. Trends Cell Biol., 1998, 8, 447-53.
13. Buxbaum, J.D.; Liu, K.N.; Luo, Y.; Slack, J.L.; Stocking, K.L.; Peschon, J.J.; Johnson, R.S.; Castner, B.J.; Cerretti, D.P.; Black, R.A. Evidence that tumor necrosis factor alpha converting enzyme is involved in regulated alpha-secretase cleavage of the Alzheimer amyloid protein precursor. J. Biol. Chem., 1998, 273, 27765-7.
14. Koike, H.; Tomioka, S.; Sorimachi, H.; Saido, T.C.; Maruyama, K.; Okuyama, A.; Fujisawa-Sehara, A.; Ohno, S.; Suzuki, K.; Ishiura, S. Membrane-anchored metalloprotease MDC9 has an alphasecretase activity responsible for processing the amyloid precursor protein. Biochem. J., 1999, 343 Pt 2, 371-5.
15. Lammich, S.; Kojro, E.; Postina, R.; Gilbert, S.; Pfeiffer, R.; Jasionowski, M.; Haass, C.; Fahrenholz, F. Constitutive and regulated alpha-secretase cleavage of Alzheimer's amyloid precursor protein by a disintegrin metalloprotease. Proc. Natl. Acad. Sci. U.S.A., 1999, 96, 3922-7.
16. Hussain, I.; Powell, D.; Howlett, D.R.; Tew, D.G.; Meek, T.D.; Chapman, C.; Gloger, I.S.; Murphy, K.E.; Southan, C.D.; Ryan, D.M.; Smith, T.S.; Simmons, D.L.; Walsh, F.S.; Dingwall, C.; Christie, G. Identification of a novel aspartic protease (Asp 2) as beta-secretase. Mol. Cell Neurosci., 1999, 14, 419-27.
17. Sinha, S.; Anderson, J.P.; Barbour, R.; Basi, G.S.; Caccavello, R.; Davis, D.; Doan, M.; Dovey, H.F.; Frigon, N.; Hong, J.; Jacobson-Croak, K.; Jewett, N.; Keim, P.; Knops, J.; Lieberburg, I.; Power, M.; Tan, H.; Tatsuno, G.; Tung, J.; Schenk, D.; Seubert, P.; Suomensaari, S.M.; Wang, S.; Walker, D.; Zhao, J.; McConlogue, L.; John, V. Purification and cloning of amyloid precursor protein beta-secretase from human brain. Nature, 1999, 402, 537-40.
18. Vassar, R.; Bennett, B.D.; Babu-Khan, S.; Kahn, S.; Mendiaz, E.A.; Denis, P.; Teplow, D.B.; Ross, S.; Amarante, P.; Loeloff, R.; Luo, Y.; Fisher, S.; Fuller, L.; Edenson, S.; Lile, J.; Jarosinski, M.A.; Biere, A.L.; Curran, E.; Burgess, T.; Louis, J.C.; Collins, F.; Treanor, J.; Rogers, G.; Citron, M. beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. Science, 1999, 286, 735-741.
19. Yan, R.; Bienkowski, M.J.; Shuck, M.E.; Miao, H.; Tory, M.C.; Pauley, A.M.; Brashier, J.R.; Stratman, N.C.; Mathews, W.R.; Buhl, A.E.; Carter, D.B.; Tomasselli, A.G.; Parodi, L.A.; Heinrikson, R.L.; Gurney, M.E. Membrane-anchored aspartyl protease with Alzheimer's disease beta-secretase activity. Nature, 1999, 402, 533-7.
20. Lin, X.; Koelsch, G.; Wu, S.; Downs, D.; Dashti, A.; Tang, J. Human aspartic protease memapsin 2 cleaves the beta-secretase site of beta-amyloid precursor protein. Proc. Natl. Acad. Sci. U. S. A., 2000, 97, 1456-60.
21. Haque, A.; Banik, N.L.; Ray, S.K. New insights into the roles of endolysosomal cathepsins in the pathogenesis of Alzheimer's disease: cathepsin inhibitors as potential therapeutics. CNS Neurol. Disord. Drug Targets, 2008, 7, 270-7.
22. Hook, V.Y.; Kindy, M.; Hook, G. Inhibitors of cathepsin B improve memory and reduce beta-amyloid in transgenic Alzheimer disease mice expressing the wild-type, but not the Swedish mutant, beta-secretase site of the amyloid precursor protein. J. Biol. Chem., 2008, 283, 7745-53.
23. Ehehalt, R.; Keller, P.; Haass, C.; Thiele, C.; Simons, K. Amyloidogenic processing of the Alzheimer beta-amyloid precursor protein depends on lipid rafts. J. Cell Biol., 2003, 160, 113-23.
24. Sakurai, T.; Kaneko, K.; Okuno, M.; Wada, K.; Kashiyama, T.; Shimizu, H.; Akagi, T.; Hashikawa, T.; Nukina, N. Membrane microdomain switching: a regulatory mechanism of amyloid precursor protein processing. J. Cell Biol., 2008, 183, 339-52.
25. Hunt, C.E. and Turner, A.J. Cell biology, regulation and inhibition of beta-secretase (BACE-1). FEBS J., 2009, 276, 1845-59.
26. O'Connor, T.; Sadleir, K.R.; Maus, E.; Velliquette, R.A.; Zhao, J.; Cole, S.L.; Eimer, W.A.; Hitt, B.; Bembinster, L.A.; Lammich, S.; Lichtenthaler, S.F.; Hebert, S.S.; De Strooper, B.; Haass, C.; Bennett, D.A.; Vassar, R. Phosphorylation of the translation initiation factor eIF2alpha increases BACE1 levels and promotes amyloidogenesis. Neuron, 2008, 60, 988-1009.
27. Li, H.; Wolfe, M.S. Selkoe, D.J. Toward structural elucidation of the gamma-secretase complex. Structure, 2009, 17, 326-334.
28. Esler, W.P.; Kimberly, W.T.; Ostaszewski, B.L.; Diehl, T.S.; Moore, C.L.; Tsai, J.Y.; Rahmati, T.; Xia, W.; Selkoe, D.J.; Wolfe, M.S. Transition-state analogue inhibitors of gamma-secretase bind directly to presenilin-1. Nat. Cell Biol., 2000, 2, 428-34.
29. Wolfe, M.S.; Xia, W.; Ostaszewski, B.L.; Diehl, T.S.; Kimberly, W.T.; Selkoe, D.J. Two transmembrane aspartates in presenilin-1 required for presenilin endoproteolysis and gamma-secretase activity. Nature, 1999, 398, 513-7.
30. Scheper, W.; Annaert, W.; Cupers, P.; P., S. De Strooper, B. Function and dysfunction of the presenilins. Alzheimer's Reports, 1999, 2, 1-9.
31. Tolia, A. and De Strooper, B. Structure and function of gammasecretase. Semin.Cell Dev.Biol., 2009, 20, 211-218.
32. Hoozemans, J.J.; Chafekar, S.M.; Baas, F.; Eikelenboom, P.; Scheper, W. Always around, never the same: pathways of amyloid beta induced neurodegeneration throughout the pathogenic cascade of Alzheimer's disease. Curr. Med. Chem., 2006, 13, 2599-605.
33. LaFerla, F.M.; Green, K.N.; Oddo, S. Intracellular amyloid-beta in Alzheimer's disease. Nat. Rev. Neurosci., 2007, 8, 499-509.
34. Selkoe, D.J. Cell biology of protein misfolding: the examples of Alzheimer's and Parkinson's diseases. Nat. Cell Biol., 2004, 6, 1054-61.
35. Klyubin, I.; Walsh, D.M.; Lemere, C.A.; Cullen, W.K.; Shankar, G.M.; Betts, V.; Spooner, E.T.; Jiang, L.; Anwyl, R.; Selkoe, D.J.; Rowan, M.J. Amyloid beta protein immunotherapy neutralizes Abeta oligomers that disrupt synaptic plasticity in vivo. Nat. Med., 2005, 11, 556-61.
36. Walsh, D.M.; Klyubin, I.; Fadeeva, J.V.; Cullen, W.K.; Anwyl, R.; Wolfe, M.S.; Rowan, M.J.; Selkoe, D.J. Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal longterm potentiation in vivo. Nature, 2002, 416, 535-9.
37. Walsh, D.M. and Selkoe, D.J. A beta oligomers - a decade of discovery. J. Neurochem., 2007, 101, 1172-84.
38. Amijee, H. and Scopes, D.I. The quest for small molecules as amyloid inhibiting therapies for Alzheimer's disease. J. Alzheimers. Dis., 2009, 17, 33-47.
39. Bitan, G.; Fradinger, E.A.; Spring, S.M.; Teplow, D.B. Neurotoxic protein oligomers - what you see is not always what you get. Amyloid, 2005, 12, 88-95.
40. Necula, M.; Kayed, R.; Milton, S.; Glabe, C.G. Small molecule inhibitors of aggregation indicate that amyloid beta oligomerization and fibrillization pathways are independent and distinct. J. Biol. Chem., 2007, 282, 10311-24.
41. Chromy, B.A.; Nowak, R.J.; Lambert, M.P.; Viola, K.L.; Chang, L.; Velasco, P.T.; Jones, B.W.; Fernandez, S.J.; Lacor, P.N.; Horowitz, P.; Finch, C.E.; Krafft, G.A.; Klein, W.L. Self-assembly of Abeta(1-42) into globular neurotoxins. Biochemistry, 2003, 42, 12749-60.
42. Nichols, M.R.; Moss, M.A.; Reed, D.K.; Lin, W.L.; Mukhopadhyay, R.; Hoh, J.H.; Rosenberry, T.L. Growth of betaamyloid( 1-40) protofibrils by monomer elongation and lateral association. Characterization of distinct products by light scattering and atomic force microscopy. Biochemistry, 2002, 41, 6115-27.
43. Tseng, B.P.; Esler, W.P.; Clish, C.B.; Stimson, E.R.; Ghilardi, J.R.; Vinters, H.V.; Mantyh, P.W.; Lee, J.P.; Maggio, J.E. Deposition of monomeric, not oligomeric, Abeta mediates growth of Alzheimer's disease amyloid plaques in human brain preparations. Biochemistry, 1999, 38, 10424-31.
44. Harper, J.D.; Lieber, C.M.; Lansbury, P.T., Jr. Atomic force microscopic imaging of seeded fibril formation and fibril branching by the Alzheimer's disease amyloid-beta protein. Chem. Biol., 1997, 4, 951-9.
45. Harper, J.D. and Lansbury, P.T., Jr. Models of amyloid seeding in Alzheimer's disease and scrapie: mechanistic truths and physiological consequences of the time-dependent solubility of amyloid proteins. Annu. Rev. Biochem., 1997, 66, 385-407.
46. Teplow, D.B. Structural and kinetic features of amyloid betaprotein fibrillogenesis. Amyloid, 1998, 5, 121-42.
47. Hayashi, H.; Kimura, N.; Yamaguchi, H.; Hasegawa, K.; Yokoseki, T.; Shibata, M.; Yamamoto, N.; Michikawa, M.; Yoshikawa, Y.; Terao, K.; Matsuzaki, K.; Lemere, C.A.; Selkoe, D.J.; Naiki, H.; Yanagisawa, K. A seed for Alzheimer amyloid in the brain. J. Neurosci., 2004, 24, 4894-902.
48. McGowan, E.; Pickford, F.; Kim, J.; Onstead, L.; Eriksen, J.; Yu, C.; Skipper, L.; Murphy, M.P.; Beard, J.; Das, P.; Jansen, K.; Delucia, M.; Lin, W.L.; Dolios, G.; Wang, R.; Eckman, C.B.; Dickson, D.W.; Hutton, M.; Hardy, J.; Golde, T. Abeta42 is essential for parenchymal and vascular amyloid deposition in mice. Neuron, 2005, 47, 191-9.
49. He, W. and Barrow, C.J. The A beta 3-pyroglutamyl and 11-pyroglutamyl peptides found in senile plaque have greater betasheet forming and aggregation propensities in vitro than full-length A beta. Biochemistry, 1999, 38, 10871-10877.
50. Pike, C.J.; Overman, M.J.; Cotman, C.W. Amino-terminal deletions enhance aggregation of beta-amyloid peptides in vitro. J. Biol. Chem., 1995, 270, 23895-8.
51. Schilling, S.; Lauber, T.; Schaupp, M.; Manhart, S.; Scheel, E.; Bohm, G.; Demuth, H.U. On the seeding and oligomerization of pGlu-amyloid peptides (in vitro). Biochemistry, 2006, 45, 12393-12399.
52. Selkoe, D.J. Clearing the brain's amyloid cobwebs. Neuron, 2001, 32, 177-180.
53. Rawlings, N.D. and Barrett, A.J. Evolutionary families of peptidases. Biochem. J., 1993, 290, 205-218.
54. Erdos, E.G. and Skidgel, R.A. Neutral endopeptidase 24.11 (Enkephalinase) and related regulators of peptide-hormones. FASEB J., 1989, 3, 145-151.
55. Howell, S.; Nalbantoglu, J.; Crine, P. Neutral endopeptidase can hydrolyze beta-amyloid(1-40) but shows no effect on beta-amyloid precursor protein-metabolism. Peptides, 1995, 16, 647-652.
56. Leissring, M.A.; Lu, A.; Condron, M.M.; Teplow, D.B.; Stein, R.L.; Farris, W.; Selkoe, D.J. Kinetics of amyloid beta-protein degradation determined by novel fluorescence- and fluorescence polarization-based assays. J.Biol.Chem., 2003, 278, 37314-37320.
57. Kanemitsu, H.; Tomiyama, T.; Mori, H. Human neprilysin is capable of degrading amyloid beta peptide not only in the monomeric form but also the pathological oligomeric form. Neurosci. Lett., 2003, 350, 113-116.
58. Iwata, N.; Tsubuki, S.; Takaki, Y.; Watanabe, K.; Sekiguchi, M.; Hosoki, E.; Kawashima-Morishima, M.; Lee, H.J.; Hama, E.; Sekine-Aizawa, Y.; Saido, T.C. Identification of the major A beta(1-42) -degrading catabolic pathway in brain parenchyma: Suppression leads to biochemical and pathological deposition. Nat. Med., 2000, 6, 143-150.
59. Iwata, N.; Tsubuki, S.; Takaki, Y.; Shirotani, K.; Lu, B.; Gerard, N.P.; Gerard, C.; Hama, E.; Lee, H.J.; Saido, T.C. Metabolic regulation of brain A beta by neprilysin. Science, 2001, 292, 1550-1552.
60. El Amouri, S.S.; Zhu, H.; Yu, J.; Marr, R.; Verma, I.M.; Kindy, M.S. Neprilysin: An enzyme candidate to slow the progression of Alzheimer's disease. Am. J. Pathol., 2008, 172, 1342-1354.
61. Leissring, M.A.; Farris, W.; Chang, A.Y.; Walsh, D.M.; Wu, X.; Sun, X.; Frosch, M.P.; Selkoe, D.J. Enhanced proteolysis of betaamyloid in APP transgenic mice prevents plaque formation, secondary pathology, and premature death. Neuron, 2003, 40, 1087-1093.
62. Poirier, R.; Wolfer, D.P.; Welzl, H.; Tracy, J.; Galsworthy, M.J.; Nitsch, R.M.; Mohajeri, M.H. Neuronal neprilysin overexpression is associated with attenuation of Abeta-related spatial memory deficit. Neurobiol.Dis., 2006, 24, 475-483.
63. Hellstrom-Lindahl, E.; Ravid, R.; Nordberg, A. Age-dependent decline of neprilysin in Alzheimer's disease and normal brain: inverse correlation with A beta levels. Neurobiol. Aging, 2008, 29, 210-221.
64. Kurochkin, I.V. Insulin-degrading enzyme: embarking on amyloid destruction. Trends Biochem.Sci., 2001, 26, 421-425.
65. Chesneau, V.; Vekrellis, K.; Rosner, M.R.; Selkoe, D.J. Purified recombinant insulin-degrading enzyme degrades amyloid betaprotein but does not promote its oligomerization. Biochem. J., 2000, 351, 509-516.
66. Qiu, W.Q.; Walsh, D.M.; Ye, Z.; Vekrellis, K.; Zhang, J.M.; Podlisny, M.B.; Rosner, M.R.; Safavi, A.; Hersh, L.B.; Selkoe, D.J. Insulin-degrading enzyme regulates extracellular levels of amyloid beta-protein by degradation. J. Biol. Chem., 1998, 273, 32730-32738.
67. Authier, F.; Posner, B.I.; Bergeron, J.J. Insulin-degrading enzyme. Clin. Invest. Med., 1996, 19, 149-160.
68. Duckworth, W.C.; Bennett, R.G.; Hamel, F.G. Insulin degradation: progress and potential. Endocr. Rev., 1998, 19, 608-624.
69. Zhao, J.; Li, L.; Leissring, M.A. Insulin-degrading enzyme is exported via an unconventional protein secretion pathway. Mol. Neurodegener., 2009, 4, 4.
70. Leissring, M.A.; Farris, W.; Wu, X.; Christodoulou, D.C.; Haigis, M.C.; Guarente, L.; Selkoe, D.J. Alternative translation initiation generates a novel isoform of insulin-degrading enzyme targeted to mitochondria. Biochem. J., 2004, 383, 439-446.
71. Hansson Petersen, C.A.; Alikhani, N.; Behbahani, H.; Wiehager, B.; Pavlov, P.F.; Alafuzoff, I.; Leinonen, V.; Ito, A.; Winblad, B.; Glaser, E.; Ankarcrona, M. The amyloid beta-peptide is imported into mitochondria via the TOM import machinery and localized to mitochondrial cristae. Proc. Natl. Acad. Sci. U.S.A., 2008, 105, 13145-13150.
72. Vekrellis, K.; Ye, Z.; Qiu, W.Q.; Walsh, D.; Hartley, D.; Chesneau, V.; Rosner, M.R.; Selkoe, D.J. Neurons regulate extracellular levels of amyloid beta-protein via proteolysis by insulin-degrading enzyme. J. Neurosci., 2000, 20, 1657-1665.
73. Morelli, L.; Llovera, R.; Gonzalez, S.A.; Affranchino, J.L.; Prelli, F.; Frangione, B.; Ghiso, J.; Castano, E.M. Differential degradation of amyloid beta genetic variants associated with hereditary dementia or stroke by insulin-degrading enzyme. J. Biol. Chem., 2003, 278, 23221-23226.
74. Kurochkin, I.V. and Goto, S. Alzheimers beta-amyloid peptide specifically interacts with and is degraded by insulin degrading enzyme. FEBS Lett., 1994, 345, 33-37.
75. Farris, W.; Mansourian, S.; Chang, Y.; Lindsley, L.; Eckman, E.A.; Frosch, M.P.; Eckman, C.B.; Tanzi, R.E.; Selkoe, D.J.; Guenette, S. Insulin-degrading enzyme regulates the levels of insulin, amyloid beta-protein, and the beta-amyloid precursor protein intracellular domain in vivo. Proc. Natl. Acad. Sci. U.S.A., 2003, 100, 4162-4167.
76. Miller, B.C.; Eckman, E.A.; Sambamurti, K.; Dobbs, N.; Chow, K.M.; Eckman, C.B.; Hersh, L.B.; Thiele, D.L. Amyloid-beta peptide levels in brain are inversely correlated with insulysin activity levels in vivo. Proc. Natl. Acad. Sci. U.S.A., 2003, 100, 6221-6226.
77. Bernstein, H.G.; Ansorge, S.; Riederer, P.; Reiser, M.; Frolich, L.; Bogerts, B. Insulin-degrading enzyme in the Alzheimer's disease brain: prominent localization in neurons and senile plaques. Neurosci. Lett., 1999, 263, 161-164.
78. Perez, A.; Morelli, L.; Cresto, J.C.; Castano, E.M. Degradation of soluble amyloid beta-peptides 1-40, 1-42, and the Dutch variant 1-40Q by insulin degrading enzyme from Alzheimer disease and control brains. Neurochem. Res., 2000, 25, 247-255.
79. Cook, D.G.; Leverenz, J.B.; McMillan, P.J.; Kulstad, J.J.; Ericksen, S.; Roth, R.A.; Schellenberg, G.D.; Jin, L.W.; Kovacina, K.S.; Craft, S. Reduced hippocampal insulin-degrading enzyme in lateonset Alzheimer's disease is associated with the apolipoprotein Eepsilon4 allele. Am. J. Pathol., 2003, 162, 313-319.
80. Caccamo, A.; Oddo, S.; Sugarman, M.C.; Akbari, Y.; LaFerla, F.A. Age- and region-dependent alterations in A beta-degrading enzymes: implications for A beta-induced disorders. Neurobiol. Aging, 2005, 26, 645-654.
81. Bertram, L.; Blacker, D.; Mullin, K.; Keeney, D.; Jones, J.; Basu, S.; Yhu, S.; McInnis, M.G.; Go, R.C.P.; Vekrellis, K.; Selkoe, D.J.; Saunders, A.J.; Tanzi, R.E. Evidence for genetic linkage of Alzheimer's disease to chromosome 10q. Science, 2000, 290, 2302-3.
82. Zuo, X.M. and Jia, J.P. Promoter polymorphisms which modulate insulin degrading enzyme expression may increase susceptibility to Alzheimer's disease. Brain Res., 2009, 1249, 1-8.
83. Mori, H.; Takio, K.; Ogawara, M.; Selkoe, D.J. Mass spectrometry of purified amyloid beta protein in Alzheimer's disease. J. Biol. Chem., 1992, 267, 17082-17086.
84. Roher, A.E.; Lowenson, J.D.; Clarke, S.; Wolkow, C.; Wang, R.; Cotter, R.J.; Reardon, I.M.; Zurcher-Neely, H.A.; Heinrikson, R.L.; Ball, M.J. Structural alterations in the peptide backbone of betaamyloid core protein may account for its deposition and stability in Alzheimer's disease. J.Biol.Chem., 1993, 268, 3072-3083.
85. Tomiyama, T.; Asano, S.; Furiya, Y.; Shirasawa, T.; Endo, N.; Mori, H. Racemization of Asp23 residue affects the aggregation properties of Alzheimer amyloid beta protein analogues. J. Biol. Chem., 1994, 269, 10205-10208.
86. Geiger, T. and Clarke, S. Deamidation, isomerization, and racemization at asparaginyl and aspartyl residues in peptides. Succinimide-linked reactions that contribute to protein degradation. J. Biol. Chem., 1987, 262, 785-794.
87. Cloos, P.A. and Christgau, S. Post-translational modifications of proteins: implications for aging, antigen recognition, and autoimmunity. Biogerontology, 2004, 5, 139-158.
88. Roher, A.E.; Palmer, K.C.; Yurewicz, E.C.; Ball, M.J.; Greenberg, B.D. Morphological and biochemical analyses of amyloid plaque core proteins purified from Alzheimer disease brain tissue. J. Neurochem., 1993, 61, 1916-1926.
89. Iwatsubo, T.; Saido, T.C.; Mann, D.M.; Lee, V.M.; Trojanowski, J.Q. Full-length amyloid-beta (1-42(43)) and amino-terminally modified and truncated amyloid-beta 42(43) deposit in diffuse plaques. Am. J. Pathol., 1996, 149, 1823-1830.
90. Saido, T.C.; Yamao-Harigaya, W.; Iwatsubo, T.; Kawashima, S. Amino- and carboxyl-terminal heterogeneity of beta-amyloid peptides deposited in human brain. Neurosci. Lett., 1996, 215, 173-176.
91. Shimizu, T.; Fukuda, H.; Murayama, S.; Izumiyama, N.; Shirasawa, T. Isoaspartate formation at position 23 of amyloid beta peptide enhanced fibril formation and deposited onto senile plaques and vascular amyloids in Alzheimer's disease. J. Neurosci. Res., 2002, 70, 451-461.
92. Mori, H.; Ishii, K.; Tomiyama, T.; Furiya, Y.; Sahara, N.; Asano, S.; Endo, N.; Shirasawa, T.; Takio, K. Racemization: its biological significance on neuropathogenesis of Alzheimer's disease. Tohoku J. Exp. Med., 1994, 174, 251-262.
93. Fukuda, H.; Shimizu, T.; Nakajima, M.; Mori, H.; Shirasawa, T. Synthesis, aggregation, and neurotoxicity of the Alzheimer's Abeta1-42 amyloid peptide and its isoaspartyl isomers. Bioorg. Med. Chem. Lett., 1999, 9, 953-956.
94. Kuo, Y.M.; Webster, S.; Emmerling, M.R.; De Lima, N.; Roher, A.E. Irreversible dimerization/tetramerization and posttranslational modifications inhibit proteolytic degradation of A beta peptides of Alzheimer's disease. Biochim. Biophys. Acta, 1998, 1406, 291-298.
95. Toropygin, I.Y.; Kugaevskaya, E.V.; Mirgorodskaya, O.A.; Elisseeva, Y.E.; Kozmin, Y.P.; Popov, I.A.; Nikolaev, E.N.; Makarov, A.A.; Kozin, S.A. The N-domain of angiotensin-converting enzyme specifically hydrolyzes the Arg-5-His-6 bond of Alzheimer's Abeta-(1-16) peptide and its isoAsp-7 analogue with different efficiency as evidenced by quantitative matrix-assisted laser desorption/ ionization time-of-flight mass spectrometry. Rapid Commun. Mass Spectrom., 2008, 22, 231-239.
96. Shimizu, T.; Watanabe, A.; Ogawara, M.; Mori, H.; Shirasawa, T. Isoaspartate formation and neurodegeneration in Alzheimer's disease. Arch. Biochem. Biophys., 2000, 381, 225-234.
97. Van Coillie, E.; Proost, P.; Van, A., I; Struyf, S.; Polfliet, M.; De, M., I; Harvey, D.J.; Van Damme, J.; Opdenakker, G. Functional comparison of two human monocyte chemotactic protein-2 isoforms, role of the amino-terminal pyroglutamic acid and processing by CD26/dipeptidyl peptidase IV. Biochemistry, 1998, 37, 12672-12680.
98. Hinke, S.A.; Pospisilik, J.A.; Demuth, H.U.; Mannhart, S.; Kuhn-Wache, K.; Hoffmann, T.; Nishimura, E.; Pederson, R.A.; McIntosh, C.H. Dipeptidyl peptidase IV (DPIV/CD26) degradation of glucagon. Characterization of glucagon degradation products and DPIV-resistant analogs. J. Biol. Chem., 2000, 275, 3827-3834.
99. Fischer, W.H. and Spiess, J. Identification of a mammalian glutaminyl cyclase converting glutaminyl into pyroglutamyl peptides. Proc. Natl. Acad. Sci. U.S.A., 1987, 84, 3628-3632.
100. Schilling, S.; Hoffmann, T.; Manhart, S.; Hoffmann, M.; Demuth, H.U. Glutaminyl cyclases unfold glutamyl cyclase activity under mild acid conditions. FEBS Lett., 2004, 563, 191-196.
101. Naslund, J.; Schierhorn, A.; Hellman, U.; Lannfelt, L.; Roses, A.D.; Tjernberg, L.O.; Silberring, J.; Gandy, S.E.; Winblad, B.; Greengard, P. Relative abundance of Alzheimer A beta amyloid peptide variants in Alzheimer disease and normal aging. Proc. Natl. Acad. Sci. U.S.A., 1994, 91, 8378-8382.
102. Cynis, H.; Scheel, E.; Saido, T.C.; Schilling, S.; Demuth, H.U. Amyloidogenic processing of amyloid precursor protein: evidence of a pivotal role of glutaminyl cyclase in generation of pyroglutamate-modified amyloid-beta. Biochemistry, 2008, 47, 7405-7413.
103. Bockers, T.M.; Kreutz, M.R.; Pohl, T. Glutaminyl-cyclase expression in the bovine/porcine hypothalamus and pituitary. J. Neuroendocrinol., 1995, 7, 445-453.
104. Saido, T.C.; Iwatsubo, T.; Mann, D.M.; Shimada, H.; Ihara, Y.; Kawashima, S. Dominant and differential deposition of distinct beta-amyloid peptide species, A beta N3(pE), in senile plaques. Neuron, 1995, 14, 457-466.
105. Harigaya, Y.; Saido, T.C.; Eckman, C.B.; Prada, C.M.; Shoji, M.; Younkin, S.G. Amyloid beta protein starting pyroglutamate at position 3 is a major component of the amyloid deposits in the Alzheimer's disease brain. Biochem. Biophys. Res. Commun., 2000, 276, 422-427.
106. Barrett, A.J. and Mcdonald, J.K. Nomenclature - Protease, Proteinase and Peptidase. Biochem. J., 1986, 237, 935-935.
107. Russo, C.; Violani, E.; Salis, S.; Venezia, V.; Dolcini, V.; Damonte, G.; Benatti, U.; D'Arrigo, C.; Patrone, E.; Carlo, P.; Schettini, G. Pyroglutamate-modified amyloid beta-peptides--AbetaN3(pE)--strongly affect cultured neuron and astrocyte survival. J. Neurochem., 2002, 82, 1480-1489.
108. Youssef, I.; Florent-Bechard, S.; Malaplate-Armand, C.; Koziel, V.; Bihain, B.; Olivier, J.L.; Leininger-Muller, B.; Kriem, B.; Oster, T.; Pillot, T. N-truncated amyloid-beta oligomers induce learning impairment and neuronal apoptosis. Neurobiol. Aging, 2008, 29, 1319-1333.
109. Schilling, S.; Zeitschel, U.; Hoffmann, T.; Heiser, U.; Francke, M.; Kehlen, A.; Holzer, M.; Hutter-Paier, B.; Prokesch, M.; Windisch, M.; Jagla, W.; Schlenzig, D.; Lindner, C.; Rudolph, T.; Reuter, G.; Cynis, H.; Montag, D.; Demuth, H.U.; Rossner, S. Glutaminyl cyclase inhibition attenuates pyroglutamate A beta and Alzheimer's disease-like pathology. Nat. Med., 2008, 14, 1106-1111.
110. Hsia, A.Y.; Masliah, E.; McConlogue, L.; Yu, G.Q.; Tatsuno, G.; Hu, K.; Kholodenko, D.; Malenka, R.C.; Nicoll, R.A.; Mucke, L. Plaque-independent disruption of neural circuits in Alzheimer's disease mouse models. Proc. Natl. Acad. Sci. U.S.A., 1999, 96, 3228-33.
111. Oddo, S.; Caccamo, A.; Shepherd, J.D.; Murphy, M.P.; Golde, T.E.; Kayed, R.; Metherate, R.; Mattson, M.P.; Akbari, Y.; La-Ferla, F.M. Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction. Neuron, 2003, 39, 409-21.
112. Rutten, B.P.; Van der Kolk, N.M.; Schafer, S.; van Zandvoort, M.A.; Bayer, T.A.; Steinbusch, H.W.; Schmitz, C. Age-related loss of synaptophysin immunoreactive presynaptic boutons within the hippocampus of APP751SL, PS1M146L, and APP751SL/ PS1M146L transgenic mice. Am. J. Pathol., 2005, 167, 161-73.
113. Lauren, J.; Gimbel, D.A.; Nygaard, H.B.; Gilbert, J.W.; Strittmatter, S.M. Cellular prion protein mediates impairment of synaptic plasticity by amyloid-beta oligomers. Nature, 2009, 457, 1128-32.
114. Hoozemans, J.J.; Veerhuis, R.; Van Haastert, E.S.; Rozemuller, J.M.; Baas, F.; Eikelenboom, P.; Scheper, W. The unfolded protein response is activated in Alzheimer's disease. Acta Neuropathol. (Berl), 2005, 110, 165-172.
115. Hoozemans, J.J.M.; Van Haastert, E.S.; Nijholt, D.A.T.; Rozemuller, A.J.M.; Eikelenboom, P.; Scheper, W. The Unfolded Protein Response is activated in pretangle neurons in Alzheimer's disease hippocampus. Am. J. Pathol., 2009, 174, 1241-51.
116. Chafekar, S.M.; Hoozemans, J.J.; Zwart, R.; Baas, F.; Scheper, W. Abeta 1-42 induces mild endoplasmic reticulum stress in an aggregation state-dependent manner. Antioxid. Redox. Signal., 2007, 9, 2245-54.
117. Chafekar, S.M.; Zwart, R.; Veerhuis, R.; Vanderstichele, H.; Baas, F.; Scheper, W. Increased Abeta1-42 production sensitizes neuroblastoma cells for ER stress toxicity. Curr. Alzheimer Res., 2008, 5, 469-74.
118. Demuro, A.; Mina, E.; Kayed, R.; Milton, S.C.; Parker, I.; Glabe, C.G. Calcium dysregulation and membrane disruption as a ubiquitous neurotoxic mechanism of soluble amyloid oligomers. J. Biol. Chem., 2005, 280, 17294-300.
119. Chafekar, S.M.; Baas, F.; Scheper, W. Oligomer-specific Abeta toxicity in cell models is mediated by selective uptake. Biochim. Biophys. Acta., 2008, 1782, 523-31.
120. Eikelenboom, P.; Veerhuis, R.; Scheper, W.; Rozemuller, A.J.; van Gool, W.A.; Hoozemans, J.J. The significance of neuroinflamma tion in understanding Alzheimer's disease. J. Neural. Transm., 2006, 113, 1685-95.
121. Sondag, C.M.; Dhawan, G.; Combs, C.K. Beta amyloid oligomers and fibrils stimulate differential activation of primary microglia. J. Neuroinflammation, 2009, 6, 1.
122. Herzig, M.C.; Van Nostrand, W.E.; Jucker, M. Mechanism of cerebral beta-amyloid angiopathy: murine and cellular models. Brain Pathol., 2006, 16, 40-54.
123. Kumar-Singh, S.; Julliams, A.; Nuydens, R.; Ceuterick, C.; Labeur, C.; Serneels, S.; Vennekens, K.; Van Osta, P.; Geerts, H.; De Strooper, B.; Van Broeckhoven, C. In vitro studies of Flemish, Dutch, and wild-type beta-amyloid provide evidence for two-staged neurotoxicity. Neurobiol. Dis., 2002, 11, 330-340.
124. Van Broeckhoven, C. and Kumar-Singh, S. Genetics and pathology of alpha-secretase site AbetaPP mutations in the understanding of Alzheimer's disease. J. Alzheimers Dis., 2006, 9, 389-398.
125. Fawzi, N.L.; Kohlstedt, K.L.; Okabe, Y.; Head-Gordon, T. Protofibril assemblies of the arctic, Dutch, and Flemish mutants of the Alzheimer's Abeta1-40 peptide. Biophys. J., 2008, 94, 2007-2016.
126. Lashuel, H.A.; Hartley, D.M.; Petre, B.M.; Wall, J.S.; Simon, M.N.; Walz, T.; Lansbury, P.T., Jr. Mixtures of wild-type and a pathogenic (E22G) form of Abeta40 in vitro accumulate protofibrils, including amyloid pores. J. Mol. Biol., 2003, 332, 795-808.
127. Nilsberth, C.; Westlind-Danielsson, A.; Eckman, C.B.; Condron, M.M.; Axelman, K.; Forsell, C.; Stenh, C.; Luthman, J.; Teplow, D.B.; Younkin, S.G.; Naslund, J.; Lannfelt, L. The 'Arctic' APP mutation (E693G) causes Alzheimer's disease by enhanced Abeta protofibril formation. Nat. Neurosci., 2001, 4, 887-93.
128. Betts, V.; Leissring, M.A.; Dolios, G.; Wang, R.; Selkoe, D.J.; Walsh, D.M. Aggregation and catabolism of disease-associated intra-A beta mutations: reduced proteolysis of A beta A21G by neprilysin. Neurobiol. Dis., 2008, 31, 442-450.
129. Nordberg, A. Amyloid plaque imaging in vivo: current achievement and future prospects. Eur. J. Nucl. Med. Mol. Imaging, 2008, 35 Suppl 1, S46-S50.
130. Visser, P.J.; Verhey, F.; Knol, D.L.; Scheltens, P.; Wahlund, L.O.; Freund-Levi, Y.; Tsolaki, M.; Minthon, L.; Wallin, A.K.; Hampel, H.; Burger, K.; Pirttila, T.; Soininen, H.; Rikkert, M.O.; Verbeek, M.M.; Spiru, L.; Blennow, K. Prevalence and prognostic value of CSF markers of Alzheimer's disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: a prospective cohort study. Lancet Neurol., 2009, 8, 619-627.
131. Roberds, S.L.; Anderson, J.; Basi, G.; Bienkowski, M.J.; Branstetter, D.G.; Chen, K.S.; Freedman, S.B.; Frigon, N.L.; Games, D.; Hu, K.; Johnson-Wood, K.; Kappenman, K.E.; Kawabe, T.T.; Kola, I.; Kuehn, R.; Lee, M.; Liu, W.; Motter, R.; Nichols, N.F.; Power, M.; Robertson, D.W.; Schenk, D.; Schoor, M.; Shopp, G.M.; Shuck, M.E.; Sinha, S.; Svensson, K.A.; Tatsuno, G.; Tintrup, H.; Wijsman, J.; Wright, S.; McConlogue, L. BACE knockout mice are healthy despite lacking the primary beta-secretase activity in brain: implications for Alzheimer's disease therapeutics. Hum. Mol. Genet., 2001, 10, 1317-24.
132. Hu, X.; Hicks, C.W.; He, W.; Wong, P.; Macklin, W.B.; Trapp, B.D.; Yan, R. Bace1 modulates myelination in the central and peripheral nervous system. Nat. Neurosci., 2006, 9, 1520-5.
133. Willem, M.; Garratt, A.N.; Novak, B.; Citron, M.; Kaufmann, S.; Rittger, A.; DeStrooper, B.; Saftig, P.; Birchmeier, C.; Haass, C. Control of peripheral nerve myelination by the beta-secretase BACE1. Science, 2006, 314, 664-6.
134. Kitazume, S.; Tachida, Y.; Oka, R.; Shirotani, K.; Saido, T.C.; Hashimoto, Y. Alzheimer's beta-secretase, beta-site amyloid precursor protein-cleaving enzyme, is responsible for cleavage secretion of a Golgi-resident sialyltransferase. Proc. Natl. Acad. Sci. U.S.A., 2001, 98, 13554-9.
135. Lichtenthaler, S.F.; Dominguez, D.I.; Westmeyer, G.G.; Reiss, K.; Haass, C.; Saftig, P.; De Strooper, B.; Seed, B. The cell adhesion protein P-selectin glycoprotein ligand-1 is a substrate for the aspartyl protease BACE1. J. Biol. Chem., 2003, 278, 48713-9.
136. von Arnim, C.A.; Kinoshita, A.; Peltan, I.D.; Tangredi, M.M.; Herl, L.; Lee, B.M.; Spoelgen, R.; Hshieh, T.T.; Ranganathan, S.; Battey, F.D.; Liu, C.X.; Bacskai, B.J.; Sever, S.; Irizarry, M.C.; Strickland, D.K.; Hyman, B.T. The low density lipoprotein receptor-related protein (LRP) is a novel beta-secretase (BACE1) substrate. J. Biol. Chem., 2005, 280, 17777-85.
137. Wong, H.K.; Sakurai, T.; Oyama, F.; Kaneko, K.; Wada, K.; Miyazaki, H.; Kurosawa, M.; De Strooper, B.; Saftig, P.; Nukina, N. Beta Subunits of voltage-gated sodium channels are novel substrates of beta-site amyloid precursor protein-cleaving enzyme (BACE1) and gamma-secretase. J. Biol. Chem., 2005, 280, 23009-17.
138. Fleisher, A.S.; Raman, R.; Siemers, E.R.; Becerra, L.; Clark, C.M.; Dean, R.A.; Farlow, M.R.; Galvin, J.E.; Peskind, E.R.; Quinn, J.F.; Sherzai, A.; Sowell, B.B.; Aisen, P.S.; Thal, L.J. Phase 2 safety trial targeting amyloid beta production with a gamma-secretase inhibitor in Alzheimer disease. Arch. Neurol., 2008, 65, 1031-8.
139. Albright, C.; Dockens, R.; Olson, R.; Jere, M.; Slemmon, R.; Lentz, K.; Wang, J.; Denton, R.; Pilcher, G.; Zacaek, R.; Macor, J.; Wong, O.; Gu, H.; Berman, R.; Tong, G. BMS-708163, a potent and selective gamma-secretase inhibitor, decreases CSF Aß at safe and tolerable doses in animals and humans., International Conference on Alzheimer's Disease, July 26-31, Chicago, Illinois. (Abstract HT-01-05) (2008).
140. Real, P.J.; Tosello, V.; Palomero, T.; Castillo, M.; Hernando, E.; de Stanchina, E.; Sulis, M.L.; Barnes, K.; Sawai, C.; Homminga, I.; Meijerink, J.; Aifantis, I.; Basso, G.; Cordon-Cardo, C.; Ai, W.; Ferrando, A. Gamma-secretase inhibitors reverse glucocorticoid resistance in T cell acute lymphoblastic leukemia. Nat. Med., 2009, 15, 50-8.
141. Weggen, S.; Eriksen, J.L.; Das, P.; Sagi, S.A.; Wang, R.; Pietrzik, C.U.; Findlay, K.A.; Smith, T.E.; Murphy, M.P.; Bulter, T.; Kang, D.E.; Marquez-Sterling, N.; Golde, T.E.; Koo, E.H. A subset of NSAIDs lower amyloidogenic Abeta42 independently of cyclooxygenase activity. Nature, 2001, 414, 212-6.
142. Wilcock, G.K.; Black, S.E.; Hendrix, S.B.; Zavitz, K.H.; Swabb, E.A.; Laughlin, M.A. Efficacy and safety of tarenflurbil in mild to moderate Alzheimer's disease: a randomised phase II trial. Lancet Neurol., 2008, 7, 483-93.
143. Garcia-Alloza, M.; Subramanian, M.; Thyssen, D.; Borrelli, L.A.; Fauq, A.; Das, P.; Golde, T.E.; Hyman, B.T.; Bacskai, B.J. Existing plaques and neuritic abnormalities in APP:PS1 mice are not affected by administration of the gamma-secretase inhibitor LY-411575. Mol. Neurodegener., 2009, 4, 19.
144. Serneels, L.; Van Biervliet, J.; Craessaerts, K.; Dejaegere, T.; Horre, K.; Van Houtvin, T.; Esselmann, H.; Paul, S.; Schafer, M.K.; Berezovska, O.; Hyman, B.T.; Sprangers, B.; Sciot, R.; Moons, L.; Jucker, M.; Yang, Z.; May, P.C.; Karran, E.; Wiltfang, J.; D'Hooge, R.; De Strooper, B. Gamma-secretase heterogeneity in the aph1 subunit: Relevance for Alzheimer's disease. Science, 2009, 324, 639-642.
145. Thathiah, A.; Spittaels, K.; Hoffmann, M.; Staes, M.; Cohen, A.; Horre, K.; Vanbrabant, M.; Coun, F.; Baekelandt, V.; Delacourte, A.; Fischer, D.F.; Pollet, D.; De Strooper, B.; Merchiers, P. The orphan G protein-coupled receptor 3 modulates amyloid-beta peptide generation in neurons. Science, 2009, 323, 946-51.
146. Muller, T.; Meyer, H.E.; Egensperger, R.; Marcus, K. The amyloid precursor protein intracellular domain (AICD) as modulator of gene expression, apoptosis, and cytoskeletal dynamics - Relevance for Alzheimer's disease. Prog. Neurobiol., 2008, 85, 393-406.
147. Taylor, C.J.; Ireland, D.R.; Ballagh, I.; Bourne, K.; Marechal, N.M.; Turner, P.R.; Bilkey, D.K.; Tate, W.P.; Abraham, W.C. Endogenous secreted amyloid precursor protein-alpha regulates hippocampal NMDA receptor function, long-term potentiation and spatial memory. Neurobiol. Dis., 2008, 31, 250-260.
148. Turner, P.R.; O'Connor, K.; Tate, W.P.; Abraham, W.C. Roles of amyloid precursor protein and its fragments in regulating neural activity, plasticity and memory. Prog. Neurobiol., 2003, 70, 1-32.
149. Wolfe, M.S. gamma-Secretase in biology and medicine. Semin. Cell Dev. Biol., 2009, 20, 219-224.
150. Postina, R. A closer look at alpha-secretase. Curr. Alzheimer Res., 2008, 5, 179-186.
151. Deuss, M.; Reiss, K.; Hartmann, D. Part-time alpha-secretases: The functional biology of ADAM 9, 10 and 17. Curr. Alzheimer Res., 2008, 5, 187-201.
152. Marcade, M.; Bourdin, J.; Loiseau, N.; Peillon, H.; Rayer, A.; Drouin, D.; Schweighoffer, F.; Desire, L. Etazolate, a neuroprotective drug linking GABA(A) receptor pharmacology to amyloid precursor protein processing. J. Neurochem., 2008, 106, 392-404.
153. Amijee, H. and Scopes, D.I. The Quest for Small Molecules as Amyloid Inhibiting Therapies for Alzheimer's Disease. J. Alzheimers Dis., 2009, 17, 33-47.
154. Aisen, P.S.; Gauthier, S.; Vellas, B.; Briand, R.; Saurnier, D.; Laurin, J.; Garceau, D. Alzhemed: A potential treatment for Alzheimer's disease. Curr. Alzheimer Res., 2007, 4, 473-478.
155. Santa-Maria, I.; Hernandez, F.; Del Rio, J.; Moreno, F.J.; Avila, J. Tramiprosate, a drug of potential interest for the treatment of Alzheimer's disease, promotes an abnormal aggregation of tau. Mol. Neurodegener., 2007, 2, 17.
156. Bush, A.I. and Tanzi, R.E. Therapeutics for Alzheimer's disease based on the Metal Hypothesis. Neurotherapeutics, 2008, 5, 421-432.
157. Sampson, E.; Jenagaratnam, L.; McShane, R. Metal protein attenuating compounds for the treatment of Alzheimer's disease. Cochrane Database Syst. Rev., 2008, 1, CD005380.
158. Lowe, T.L.; Strzelec, A.; Kiessling, L.L.; Murphy, R.M. Structurefunction relationships for inhibitors of beta-amyloid toxicity containing the recognition sequence KLVFF. Biochemistry, 2001, 40, 7882-7889.
159. Doig, A.J. Peptide inhibitors of beta-amyloid aggregation. Current Opinion in Drug Discovery & Development, 2007, 10, 533-539.
160. Austen, B.M.; Paleologou, K.E.; Ali, S.A.; Qureshi, M.M.; Allsop, D.; El Agnaf, O.M. Designing peptide inhibitors for oligomerization and toxicity of Alzheimer's beta-amyloid peptide. Biochemistry, 2008, 47, 1984-1992.
161. Zhang, G.; Leibowitz, M.J.; Sinko, P.J.; Stein, S. Multiple-peptide conjugates for binding beta-amyloid plaques of Alzheimer's disease. Bioconjug. Chem., 2003, 14, 86-92.
162. Chafekar, S.M.; Malda, H.; Merkx, M.; Meijer, E.W.; Viertl, D.; Lashuel, H.A.; Baas, F.; Scheper, W. Branched KLVFF tetramers strongly potentiate inhibition of beta-amyloid aggregation. Chembiochem, 2007, 8, 1857-64.
163. Chacon, M.A.; Barria, M.I.; Soto, C.; Inestrosa, N.C. Beta-sheet breaker peptide prevents Abeta-induced spatial memory impairments with partial reduction of amyloid deposits. Mol. Psychiatry, 2004, 9, 953-961.
164. Saito, T.; Iwata, N.; Tsubuki, S.; Takaki, Y.; Takano, J.; Huang, S.M.; Suemoto, T.; Higuchi, M.; Saido, T.C. Somatostatin regulates brain amyloid beta peptide A beta(42) through modulation of proteolytic degradation. Nat. Med., 2005, 11, 434-439.
165. Yang, L.L.; Ha, J.R.; Zhang, J.; Xia, W.J.; Dong, X.F.; Hu, X.Y.; Kong, F.; Cui, X. Ginsenoside Rg3 promotes beta-amyloid peptide degradation by enhancing gene expression of neprilysin. J. Pharm. Pharmacol., 2009, 61, 375-380.
166. Shen, Y.; Joachimiak, A.; Rosner, M.R.; Tang, W.J. Structures of human insulin-degrading enzyme reveal a new substrate recognition mechanism. Nature, 2006, 443, 870-874.
167. Cabrol, C.; Huzarska, M.A.; Dinolfo, C.; Rodriguez, M.C.; Reinstatler, L.; Ni, J.; Yeh, L.A.; Cuny, G.D.; Stein, R.L.; Selkoe, D.J.; Leissring, M.A. Small-molecule activators of insulin-degrading enzyme discovered through high-throughput compound screening. PLoS One., 2009, 4, e5274
168. Du, J.; Zhang, L.; Liu, S.B.; Zhang, C.; Huang, X.Q.; Li, J.; Zhao, N.M.; Wang, Z. PPAR gamma transcriptionally regulates the expression of insulin-degrading enzyme in primary neurons. Biochem. Biophys. Res. Commun., 2009, 383, 485-490.
169. Tuszynski, M.H.; Thal, L.; Pay, M.; Salmon, D.P.; Sang, U.H.; Bakay, R.; Patel, P.; Blesch, A.; Vahlsing, H.L.; Ho, G.; Tong, G.; Potkin, S.G.; Fallon, J.; Hansen, L.; Mufson, E.J.; Kordower, J.H.; Gall, C.; Conner, J. A phase 1 clinical trial of nerve growth factor gene therapy for Alzheimer disease. Nat. Med., 2005, 11, 551-555.
170. Pfeifer, A. and Verma, I.M. Gene therapy: Promises and problems. Annu. Rev. Genom. Hum. Genet., 2001, 2, 177-211.
171. Morgan, D. Immunotherapy for Alzheimer's disease. J. Alzheimers Dis., 2006, 9, 425-432.
172. Schenk, D.; Barbour, R.; Dunn, W.; Gordon, G.; Grajeda, H.; Guido, T.; Hu, K.; Huang, J.; Johnson-Wood, K.; Khan, K.; Kholodenko, D.; Lee, M.; Liao, Z.; Lieberburg, I.; Motter, R.; Mutter, L.; Soriano, F.; Shopp, G.; Vasquez, N.; Vandevert, C.; Walker, S.; Wogulis, M.; Yednock, T.; Games, D.; Seubert, P. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature, 1999, 400, 173-7.
173. Bard, F.; Cannon, C.; Barbour, R.; Burke, R.L.; Games, D.; Grajeda, H.; Guido, T.; Hu, K.; Huang, J.P.; Johnson-Wood, K.; Khan, K.; Kholodenko, D.; Lee, M.; Lieberburg, I.; Motter, R.; Nguyen, M.; Soriano, F.; Vasquez, N.; Weiss, K.; Welch, B.; Seubert, P.; Schenk, D.; Yednock, T. Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat. Med., 2000, 6, 916-919.
174. Morgan, D.; Diamond, D.M.; Gottschall, P.E.; Ugen, K.E.; Dickey, C.; Hardy, J.; Duff, K.; Jantzen, P.; DiCarlo, G.; Wilcock, D.; Connor, K.; Hatcher, J.; Hope, C.; Gordon, M.; Arendash, G.W. A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature, 2000, 408, 982-985.
175. Check, E. Nerve inflammation halts trial for Alzheimer's drug. Nature, 2002, 415, 462-462.
176. Gilman, S.; Koller, M.; Black, R.S.; Jenkins, L.; Griffith, S.G.; Fox, N.C.; Eisner, L.; Kirby, L.; Rovira, M.B.; Forette, F.; Orgogozo, J.M. Clinical effects of A beta immunization (AN1792) in patients with AD in an interrupted trial. Neurology, 2005, 64, 1553-1562.
177. Hock, C.; Konietzko, U.; Streffer, J.R.; Tracy, J.; Signorell, A.; Muller-Tillmanns, B.; Lemke, U.; Henke, K.; Moritz, E.; Garcia, E.; Wollmer, M.A.; Umbricht, D.; de Quervain, D.J.F.; Hofmann, M.; Maddalena, A.; Papassotiropoulos, A.; Nitsch, R.M. Antibodies against beta-amyloid slow cognitive decline in Alzheimer's disease. Neuron, 2003, 38, 547-554.
178. Ogawara, M.; Takahashi, M.; Shimizu, T.; Nakajima, M.; Setoguchi, Y.; Shirasawa, T. Adenoviral expression of protein-Lisoaspartyl methyltransferase (PIMT) partially attenuates the biochemical changes in PIMT-deficient mice. J. Neurosci. Res., 2002, 69, 353-361.